An Open-label Study in Healthy Subjects to Assess the Effect of Once-daily Multiple Dosing of AKB-6548 on the Pharmacokinetics of the CYP2C9 Substrate Celecoxib
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Vadadustat (Primary) ; Celecoxib
- Indications Anaemia
- Focus Pharmacokinetics
- Sponsors Akebia Therapeutics
- 23 May 2016 According to an Akebia Therapeutics media release, results of this trial were presented at the 53rd European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress.
- 23 May 2016 Results (n=12) published in an Akebia Therapeutics media release.
- 21 Oct 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.